Glioblastoma multiforme (GBM) Samples Report
2016_01_28 Data Snapshot
- Overview
+ Introduction
- Summary

There were 13 redactions, 783 replicate aliquots, 0 blacklisted aliquots, and 0 FFPE aliquots. The table below represents the sample counts for those samples that were ingested into firehose after filtering out redactions, replicates, and blacklisted data, and segregating FFPEs.

Table 1.  This table provides a breakdown of sample counts on a per sample type and, if applicable, per subtype basis. Each count is a link to a table containing a list of the samples that comprise that count and details pertaining to each individual sample (e.g. platform, sequencing center, etc.). Please note, there are usually multiple protocols per data type, so there are typically many more rows than the count implies.

Sample Type BCR Clinical CN LowP Methylation mRNA mRNASeq miR miRSeq RPPA MAF rawMAF
TP 613 595 577 0 420 540 153 565 0 233 283 283
TR 13 13 13 0 13 0 13 0 0 11 7 7
NB 505 501 488 0 0 0 0 0 0 0 0 0
NT 49 38 26 0 2 10 5 10 5 0 0 0
Totals 613 595 577 0 420 540 160 565 0 238 290 290

The sample type short letter codes in the table above are defined in the following list.

  • TP: Primary Solid Tumor

  • TR: Recurrent Solid Tumor

  • TB: Primary Blood Derived Cancer - Peripheral Blood

  • TAP: Additional - New Primary

  • TM: Metastatic

  • TAM: Additional Metastatic

  • NB: Blood Derived Normal

  • NT: Solid Tissue Normal

  • NBC: Buccal Cell Normal

  • NBM: Bone Marrow Normal

The following platforms are outdated and are not included in the counts depicted in the table above.

  • Agilent SurePrint G3 Human CGH Microarray Kit 1x1M

  • Agilent Human Genome CGH Microarray 244A

  • Agilent Human Genome CGH Custom Microarray 2x415K

  • Affymetrix Human Exon 1.0 ST Array

  • Illumina DNA Methylation OMA002 Cancer Panel I

  • Illumina DNA Methylation OMA003 Cancer Panel I

  • Illumina Human1M-Duo BeadChip

  • Illumina 550K Infinium HumanHap550 SNP Chip

Figure 1.  Get High-res Image This figure depicts the distribution of available data on a per participant basis.

- Results
+ FFPE Cases
+ Additional Annotations from the DCC's Annotations Manager
+ Methods & Data